Cookies

Like most websites The Pathologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Subspecialties Oncology

Optimizing Comprehensive Genomic Profiling and NTRK Fusion Detection in Advanced Cancers

sponsored by Illumina

Available On-Demand

1 December 2021 / 11:00 am CET

This virtual interactive case-based expert forum will be discussing NTRK fusion detection and therapeutic management of NTRK fusion driven advanced cancers. Real world application of testing modalities assessing the spectrum of genomic alterations in oncology care today including comprehensive genomic profiling, differentiating attributes of DNA and RNA workflows and testing chemistries will be reviewed in addition to the discussion of specific NTRK fusion positive Illumina cases.

Learning objectives:

  • Provide an overview of the clinical value of comprehensive genomic profiling in cancer pathology
  • Discuss real world application of testing modalities for NTRK fusion detection
  • Discuss the testing and management of patient cases in NSCLC, Thyroid Cancer, and Sarcoma

Available On-Demand

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Related Application Notes
Subspecialties Oncology
Invitae microsatellite instability detection

| Contributed by Invitae

Superior Determination of HPV using RNAscope™ In Situ Hybridization

| Contributed by Bio-Techne

Biomarker Optimization on LabSat® Research

| Contributed by Lunaphore Technologies

Related Product Profile
Diagnostics Genetics and epigenetics
QIAseq® Pan Cancer Multimodal cuts user interventions by 50%

| Contributed by QIAGEN

Most Popular
Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register